Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| (NASDAQ: EVAX) | Delayed: 3.71 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.71 | 52 Week High | $ | |||
| Open | $3.73 | 52 Week Low | $ | |||
| Day High | $3.75 | P/E | N/A | |||
| Day Low | $3.55 | EPS | $ | |||
| Volume | 107,791 | |||||
